+

WO2000061636A3 - Aberrantly glycosylated antibodies as marker for cancer - Google Patents

Aberrantly glycosylated antibodies as marker for cancer Download PDF

Info

Publication number
WO2000061636A3
WO2000061636A3 PCT/US2000/009907 US0009907W WO0061636A3 WO 2000061636 A3 WO2000061636 A3 WO 2000061636A3 US 0009907 W US0009907 W US 0009907W WO 0061636 A3 WO0061636 A3 WO 0061636A3
Authority
WO
WIPO (PCT)
Prior art keywords
iggs
cancer
aberrantly glycosylated
present inventors
found
Prior art date
Application number
PCT/US2000/009907
Other languages
French (fr)
Other versions
WO2000061636A2 (en
Inventor
Douglas D Taylor
Cicek Gercel-Taylor
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Publication of WO2000061636A2 publication Critical patent/WO2000061636A2/en
Publication of WO2000061636A3 publication Critical patent/WO2000061636A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present inventors have found that the level of aberrantly glycosylated IgGs in serum is correlated to the development of cancer. More specifically, the present inventors have found that the ratio of aberrantly glycosylated IgGs versus normal IgGs is significantly increased in cancer patients compared with normal individuals, and that such ratio increases as the cancer progresses. The present inventors have also found that the majority (up to 85%) of the tumor-reactive IgGs in cancer patients are aberrantly glycosylated. In addition, the present inventors have isolated a switching factor that induces the production of aberrantly glycosylated IgGs from antibody-producing cells. Based on these findings, the present invention provides novel methods and compositions useful for diagnosing and treating cancers.
PCT/US2000/009907 1999-04-14 2000-04-14 Aberrantly glycosylated antibodies as marker for cancer WO2000061636A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12916399P 1999-04-14 1999-04-14
US60/129,163 1999-04-14

Publications (2)

Publication Number Publication Date
WO2000061636A2 WO2000061636A2 (en) 2000-10-19
WO2000061636A3 true WO2000061636A3 (en) 2001-11-15

Family

ID=22438731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/009907 WO2000061636A2 (en) 1999-04-14 2000-04-14 Aberrantly glycosylated antibodies as marker for cancer

Country Status (1)

Country Link
WO (1) WO2000061636A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20055417A0 (en) * 2005-07-20 2005-07-20 Glykos Finland Oy Cancer-specific glycans and their use
WO2010150254A2 (en) * 2009-06-23 2010-12-29 Lab Discoveries Ltd. A method and system for the detection of cancer
WO2013036754A2 (en) * 2011-09-09 2013-03-14 The Wistar Institute Of Anatomy And Biology Methods and compositions for diagnosis of ovarian cancer
US9903870B2 (en) 2012-10-04 2018-02-27 The Wistar Institute Of Anatomy And Biology Methods and compositions for the diagnosis of ovarian cancer
WO2018220106A1 (en) * 2017-05-31 2018-12-06 Artialis Sa Biomarker molecules for sarcopenia and uses thereof
JP7469584B2 (en) * 2018-06-20 2024-04-17 東ソー株式会社 Method for isolating antibodies and method for testing diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0255342A1 (en) * 1986-07-29 1988-02-03 G.D. Searle & Co. Method of detecting or estimating biological materiel
WO1989004490A1 (en) * 1987-11-10 1989-05-18 University College London Protein glycosylation assay

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0255342A1 (en) * 1986-07-29 1988-02-03 G.D. Searle & Co. Method of detecting or estimating biological materiel
WO1989004490A1 (en) * 1987-11-10 1989-05-18 University College London Protein glycosylation assay

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAZZETT, LISA B. ET AL: "Role of asymmetric IgG as a mechanism of tumor-- survival in ovarian cancer.", GYNECOLOGIC ONCOLOGY, (JAN., 1998) VOL. 68, NO. 1, PP. 73-74. MEETING INFO.: TWENTY-NINTH ANNUAL MEETING OF THE SOCIETY OF GYNECOLOGIC ONCOLOGISTS ORLANDO, FLORIDA, USA FEBRUARY 7-11, 1998 SOCIETY OF GYNECOLOGIC ONCOLOGISTS., XP000949238 *
KELEMEN K ET AL: "A progesterone-induced protein increases the synthesis of asymmetric antibodies.", CELLULAR IMMUNOLOGY, (1996 JAN 10) 167 (1) 129-34., XP000949493 *
KEUSCH, J. ET AL.: "Analysis of different glycosylation states in IgG subclasses", CLINICA CHIMICA ACTA, vol. 252, 1996, pages 147 - 158, XP000949860 *
LIGIER, S. ET AL.: "A new antibody in rheumatoid arthritis targeting glycated IgG: IgM anti-IgG-AGE", BRITISH JOURNAL OF RHEUMATOLOGY, vol. 37, 1998, pages 1307 - 1314, XP000949856 *

Also Published As

Publication number Publication date
WO2000061636A2 (en) 2000-10-19

Similar Documents

Publication Publication Date Title
WO2000018795A3 (en) Compositions and methods for wt1 specific immunotherapy
EP2172476A3 (en) Compositions and methods for WT1 specific immunotherapy
WO1998036074A3 (en) Single and double chain antibodies to the egf receptor, derivates thereof and their use
HK1085932A1 (en) Degraded agonist antibody
WO2003008583A3 (en) Novel compositions and methods for cancer
AU2001231199A1 (en) Compositions and methods for the early diagnosis of ovarian cancer
CA2432872A1 (en) Pyrazole compounds useful as protein kinase inhibitors
WO2005005635A3 (en) Antibodies against insulin-like growth factor i receptor and uses thereof
WO2002006317A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002019963A3 (en) Synthetic erythropoiesis stimulating proteins
WO2001092581A8 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2000028090A3 (en) Diagnostic assay for cancer
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
TR199701462T1 (en) DNA Sequence and the breast-specific breast cancer protein encoded with it.
WO2002078598A3 (en) Peptides and antibodies to muc 1 proteins
WO2001075178A3 (en) Methods for identifying peptide aptamers capable of altering a cell phenotype
WO2001025273A3 (en) Compositions and methods for wt1 specific immunotherapy
WO2003046581A3 (en) Methods for diagnosis and treatment of epithelial-derived cancers,such as colorectal cancers and kidney cancers
EP2289940A3 (en) Treatment of metastatic disease
WO2003050243A3 (en) Novel genes encoding colon cancer antigens
WO2000051548A3 (en) COMPOSITIONS AND METHODS FOR THEIR PREPARATION FROM $i(LEPIDIUM)
AU2002249871A1 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
WO2003045230A3 (en) Novel compositions and methods for cancer
WO2000061636A3 (en) Aberrantly glycosylated antibodies as marker for cancer
CA2348026A1 (en) Antibodies against semp1, methods for their production and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 611577

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载